>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Anheuser-Busch InBev (BUD) upgraded to Buy from Neutral at UBS
    • Carrier Global (CARR) upgraded to Buy from Neutral at Citigroup; tgt raised to $74
    • Cinemark (CNK) upgraded to Buy from Neutral at ROTH MKM; tgt raised to $26
    • Digimarc (DMRC) upgraded to Buy from Hold at Needham; tgt $40
    • Planet Fitness (PLNT) upgraded to Buy from Hold at TD Cowen; tgt raised to $92
    • Sirius XM (SIRI) upgraded to In-line from Underperform at Evercore ISI; tgt lowered to $3.25
    • Solid Biosciences (SLDB) upgraded to Outperform from Market Perform at Leerink Partners; tgt $12
    • Synovus (SNV) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $46
  • Downgrades:
    • Liberty Media (LSXMA) downgraded to In-line from Outperform at Evercore ISI; tgt lowered to $27
    • ResMed (RMD) downgraded to Neutral from Buy at Citigroup
    • Werner Enterprises (WERN) downgraded to Negative from Neutral at Susquehanna; tgt lowered to $27
  • Others:
    • Accenture (ACN) initiated with a Neutral at Goldman; tgt $335
    • Affirm (AFRM) resumed with a Buy at Goldman; tgt $42
    • Agilysys (AGYS) initiated with an Outperform at William Blair
    • Ally Financial (ALLY) initiated with a Buy at Citigroup; tgt $50
    • Block (SQ) resumed with a Buy at Goldman; tgt $80
    • Bridger Aerospace Group (BAER) initiated with a Buy at Canaccord Genuity; tgt $5.50
    • Celsius (CELH) initiated with an Outperform at Exane BNP Paribas; tgt $87
    • Cheniere Energy Partners (CQP) initiated with a Mkt Perform at Bernstein
    • Cheniere Energy (LNG) initiated with an Outperform at Bernstein
    • Church & Dwight (CHD) initiated with a Neutral at Exane BNP Paribas; tgt $114
    • Clorox (CLX) initiated with an Underperform at Exane BNP Paribas; tgt $130
    • Coca-Cola (KO) initiated with an Outperform at Exane BNP Paribas; tgt $72
    • Cognizant Tech (CTSH) initiated with a Neutral at Goldman; tgt $72
    • Colgate-Palmolive (CL) initiated with an Outperform at Exane BNP Paribas; tgt $109
    • Elevance Health (ELV) initiated with an Overweight at Morgan Stanley; tgt $643
    • Envoy Medical (COCH) initiated with a Buy at Ascendiant Capital Markets; tgt $8.50
    • EPAM Systems (EPAM) initiated with a Neutral at Goldman; tgt $200
    • Globant (GLOB) initiated with a Buy at Goldman; tgt $200
    • Humana (HUM) initiated with an Equal-Weight at Morgan Stanley; tgt $374
    • IBM (IBM) initiated with a Buy at Goldman; tgt $200
    • IperionX (IPX) initiated with a Buy at ThinkEquity
    • Keurig Dr Pepper (KDP) initiated with a Neutral at Exane BNP Paribas; tgt $36
    • Kimberly-Clark (KMB) initiated with a Neutral at Exane BNP Paribas; tgt $146
    • Marqeta (MQ) resumed with a Neutral at Goldman; tgt $5.50
    • Monster Beverage (MNST) initiated with an Underperform at Exane BNP Paribas; tgt $48
    • PayPal (PYPL) resumed with a Neutral at Goldman; tgt $69
    • PepsiCo (PEP) initiated with a Neutral at Exane BNP Paribas; tgt $174
    • Praxis Precision Medicines (PRAX) initiated with a Buy at Needham; tgt $145
    • Procter & Gamble (PG) initiated with an Outperform at Exane BNP Paribas; tgt $187
    • TaskUs (TASK) initiated with a Sell at Goldman; tgt $12
    • Thoughtworks (TWKS) initiated with a Sell at Goldman; tgt $2.50
    • ZEEKR Intelligent Technology Holding Limited (ZK) initiated with a Buy at Citigroup; tgt $32.40

>>> US Gapping down

Gapping down
Select crypto related names showing early weakness:
  • MSTR -5.8%, BITB -5%, GBTC -5%, BTCO -5%, IBIT -4.9%, BRRR -4.7%, BTCW -4.7%, DEFI -4.6%, HIVE -4.5%, COIN -3.5%
Other news:
  • GTHX -53.2% (PRESERVE 2 did not achieve statistical significance in the primary endpoint; reaffirms guidance)
  • RMD -10.8% (shares down 12% following Eli Lilly (LLY) tirzepatide trial results; Citigroup analyst says RMD"s trial assumptions might be "optimistic" based on this data)
  • STOK -7% (discloses in SEC filing that its Chief Operating Officer and Chief Business Officer, Huw Nash Ph.D, has stepped down from position of Chief Operating Officer, effective immediately)
  • HUT -5.3% (Coatue has agreed to invest $150 million into the Company through a convertible note)
  • GOEV -3.7% (files for 13,719,850 share offering by selling shareholder; also files for 5,571,500 share offering by selling shareholder)
  • KURA -3.2% (reported preclinical data supporting the potential therapeutic utility of menin inhibitors in the treatment of diabetes)
  • TNDM -3% (Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions)
  • SON -2.9% (acquire Eviosys for ~$3.9 bln)
  • LBRDA -2.2% (announces proposed private offering of exchangeable senior debentures)
  • UAA -2% (announces agreement to settle class action litigation)
  • SBS -2% (files for ADS offering)
  • HCM -1.9% (European Commission Approval for FRUZAQLA (fruquintinib) Received by Takeda)
  • AMC -1.3% (in discussions to lower its debt load, according to Bloomberg)
  • ITI -1.2% (files for $150 mln mixed securities shelf offering)
  • CRNX -1.2% (files mixed securities shelf offering; also files for common stock offering by selling shareholders)

>>> US Gapping up

Gapping up
News:
  • ALIM +75.2% (Alimera Sciences to be acquired by ANI Pharmaceuticals (ANIP) for $5.50/share in cash)
  • ALNY +35.9% (Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations)
  • RGLS +16.6% (Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease )
  • RXO +13.8% (RXO, Inc. to acquire Coyote Logistics from UPS)
  • ALT +12.3% (Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions; Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions)
  • CANF +11.7% (Breakthrough findings demonstrate Namodenoson anti-cancer and protective effect mechanism in the liver)
  • ARGX +9.8% (FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy)
  • RGNX +8.5% (initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy )
  • CSTL +7% (announced that the latest American Gastroenterological Association clinical practice guideline recognized that not all patients with non-dysplastic BE are at low risk of developing esophageal cancer)
  • DJT +6.8% (Announces $69.4 Million in Initial Proceeds from Warrant Exercise)
  • ACET +6.6% (FDA has cleared the Company's Investigational New Drug application to evaluate ADI-270)
  • PUK +6.4% (commencement of first tranche of share buyback program)
  • DOMO +6.4% (Director disclosed the purchase of 400,000 shares at $6.58 - $7.00 worth approx. $2.7 mln)
  • FREY +6% (provides operations update)
  • CDLR +5.6% (signs firm contract for the installation of 72 15MW wind turbines at Inch Cape Offshore Wind Farm using one of Cadeler's state-of-the-art newbuild M-class wind turbine installation vessels)
  • TRDA +5% (reports positive preliminary data in healthy volunteers from phase 1 ENTR-601-44-101 trial for duchenne muscular dystrophy; entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stock in a registered direct offering for aggregate gross proceeds of ~$100 mln)
  • AVTX +5% (provides investor updates in presentation; expected cash runway thru 2027)
  • RANI +4.6% (has entered into a definitive agreement with ProGen Co. for the co-development and commercialization of RT-114, an oral RaniPill capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity)
  • GUTS +4.4% (Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions; announces advancement in weight maintenance pipeline and business updates)
  • TERN +3.2% (Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation)
  • ARWR +3.1% (presents preclinical data on new RNAi-based obesity program ARO-INHBE)
  • BHR +2.9% (Blackwells releases letter to fellow shareholders highlighting ongoing corporate piracy being carried out by Braemar Chairman Monty Bennett and His Cronies) MNKD +2.5% (Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions)
  • MUFG +2.1% (reports completion on repurchase of common stock)
  • BNTX +2.1% (BioNTech and DualityBio receive FDA Fast Track Designation for antibody-drug conjugate candidate BNT324/DB-1311 in prostate cancer)
  • TAK +1.2% (Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer; Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia)
  • VALN +1% (announces Health Canada approval of the world's first chikungunya vaccine, IXCHIQ)

NYT DealBook : Exclusive: Czech bidder for Vista raises its offer, again

Exclusive: Czech bidder for Vista raises its offer, again
The bidding war for Vista Outdoor, the parent company of CamelBak water bottles and Remington ammunition, has escalated once more.

Vista is expected to announce on Monday that it has accepted a sweetened $2 billion takeover proposal for its ammo business from the Czechoslovak Group, the Prague-based defense company, DealBook is first to report.

The details: CSG, as the Czech group is known, will now have added $90 million to its original takeover bid. (It increased its bid once before, last month.)

Under the terms of the new deal, Vista shareholders would receive $18 a share in cash for the ammo unit, known as the Kinetic Group, and one share in the company’s new publicly traded outdoor sports division.

It’s the latest twist for Vista. The company has repeatedly rejected takeover offers from MNC Capital, an investment firm run by a former Vista board member. MNC is offering more than $3 billion, which it argues is both a better financial deal and isn’t subject to the national security review that the Czech company is under.

But Vista has maintained that the CSG deal would provide more value for shareholders and that it will win national security approval.

Another bidder briefly emerged this month for Kinetic, with an offer that Vista said was “reasonably expected” to be superior to CSG’s. (While Vista hasn’t named the suitor, it was JDH Capital, an investment firm tied to the energy mogul Jeffrey Hildebrand, DealBook has confirmed after it was first reported by The Financial Times.)

Days later, however, Vista said that its new bidder had walked away; behind the scenes, MNC objected to the offer from JDH, since the two had previously explored a joint bid for Kinetic.

The new CSG deal adds another wrinkle for Vista’s annual meeting, which — after a postponement — is scheduled for July 2. One of two influential proxy advisory firms, Glass Lewis, has recommended backing the CSG offer.

But the other, Institutional Shareholder Services, changed its mind last week. It’s now recommending that shareholders abstain from voting on the deal, citing the regulatory uncertainty of the CSG bid. It supports a measure for Vista to again postpone its meeting and restart negotiations with MNC.

NYT : Apple’s European Headache

Apple’s European Headache
The iPhone maker is the first U.S. tech giant charged with breaching the European Union’s Digital Markets Act, potentially exposing it to huge fines.

The E.U. bites into Apple
Apple’s feud with global regulators escalated after the European Union on Monday charged the iPhone maker with stifling competition on its App Store, a breach that carries potentially big penalties and could upend a hugely profitable area of the tech giant’s business.
The $3 trillion company is the first to be charged under the Digital Markets Act, a landmark 2022 E.U. law that was designed to reduce the dominance of six mostly American “online gatekeepers.” Of those, Amazon, Google and Meta are also under investigation, and The Financial Times reports that Microsoft could face charges tied to its market dominance.
Here are the E.U.’s accusations against Apple:
  • The App Store violates so-called steering rules. Regulators say that app developers cannot easily inform their customers about new offerings, including cheaper deals, within Apple’s ecosystem.
  • The fees Apple charges are excessive.
  • The bloc is also investigating Apple again for noncompliance, including over a core technology fee that equates to a half-euro charge per user download.
Apple is facing a slew of regulatory hurdles at home and abroad, as the company plays catch-up in the artificial intelligence race. On Friday, Apple said it would delay rolling out new A.I. products and services in Europe because of “regulatory uncertainties.”
And the company already faces a $2 billion E.U. fine for impeding competition in the music streaming sector.

The clash is a big test for the Digital Markets Act. Under the D.M.A., fines can run as high as 20 percent of global revenue, which last year topped $380 billion at Apple. Repeat abuses would give the European Commission, the bloc’s executive arm, the additional power to force a divestment or sale.
“We are determined to use the clear and effective D.M.A. toolbox to finally open real opportunities for innovators and for consumers,” Thierry Breton, the E.U.’s internal market commissioner, said.
Apple and other tech giants are expected to challenge the scope of the markets act in court.
Apple has argued that its app store has been good for other businesses. It said on Monday that it had made a “number of changes” to the app store to comply with the D.M.A. and that it was “confident our plan complies with the law.”
A separate crackdown looms in the U.S. In March, the Justice Department, the District of Columbia and 16 states opened an antitrust suit against Apple, arguing that it designed its products so that customers are locked into the devices to the detriment of consumers and small businesses.
  • In other Apple news: the company and its longtime rival, Meta, are reportedly discussing partnering on A.I., according to The Wall Street Journal.
HERE’S WHAT’S HAPPENING
Federal prosecutors are said to recommend criminal charges against Boeing. A potential case against the embattled planemaker would arise out of accusations that it violated a 2021 settlement related to fatal 737 Max crashes in 2018 and 2019, Reuters reports. Under the terms of that agreement, Boeing agreed to overhaul its compliance practices; the company has since been under investigation for faults in more plane models.
ByteDance is reportedly working on a sanctions-compliant A.I. chip. The Chinese tech giant, which owns TikTok, is working with the American semiconductor giant Broadcom to design an advanced processor for artificial intelligence work, according to Reuters. It’s the latest effort by a Chinese company to get around U.S. sanctions that severely limit exports of advanced A.I. processors to China.

>>> Kura Oncology reported preclinical data supporting the potential therapeutic

Kura Oncology reported preclinical data supporting the potential therapeutic utility of menin inhibitors in the treatment of diabetes (20.97)
  • The new findings were presented this weekend at the American Diabetes Association's 84th Scientific Sessions in Orlando. Copies of the presentation are available in the Posters and Presentations section on Kura's website. "Despite the introduction of multiple options for the treatment of type 2 diabetes, a significant unmet need exists as a large proportion of patients do not achieve glycemic control," said Francis Burrows, Ph.D., Senior Vice President, Translational Research.
  • "We are encouraged by these preclinical data for ziftomenib in diabetes, which demonstrate the potential for menin inhibitors to enhance pancreatic function and warrant further evaluation in diabetes."
  • Type 2 diabetes is marked by an inadequate number of functional pancreatic beta cells, which results in insufficient insulin production, leading to hyperglycemia. Ziftomenib demonstrated meaningful levels of glycemic control in preclinical in vivo models, including reduced fasting blood glucose levels and %HbA1C within 27 days as well as consistent improvement in both insulin sensitivity and insulin production. The data show that the effects of ziftomenib were fully maintained following dose discontinuation, suggesting restoration of beta-cell mass. A decline in pancreatic beta-cell function and/or mass has been defined as a key contributing factor to disease progression in type 2 diabetes. Notably, in human islet microtissues originating from two donor samples, ziftomenib induced beta-cell proliferation while non-beta-cell proliferation was not detectable, demonstrating menin is a viable therapeutic target for beta-cell mass specific expansion.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • RXO +11.8%, ARGX +8.5%, ALT +8.4%, DJT +7.3%, PUK +6.5%, CDLR +5.6%, FREY +4.2%, NXE +4.2%, MNKD +3.7%, TERN +3.7%, BHR +2.9%, MUFG +2%, GUTS +2%, BNTX +1.8%, TAK +1.3%, VALN +1%, GSK +0.7%, BMY +0.7%
  • Gapping down:
    • GTHX -17.7%, RMD -12.1%, STOK -7%, MSTR -5.9%, BITB -5%, HIVE -4.9%, GBTC -4.8%, IBIT -4.8%, BRRR -4.6%, BTCO -4.6%, COIN -3.7%, HUT -3.3%, GOEV -3.2%, TNDM -3%, UAA -2.9%, SBS -2%, HCM -1.9%, DEFI -1.9%, AISP -1.6%, ITI -1.2%, CRNX -1.2%, CX -1.1%, BV -0.8%

FT : Private equity sale of can maker is rare windfall from faded buyout boom

Private equity sale of can maker is rare windfall from faded buyout boom
KPS deal to sell Eviosys comes as dealmakers have struggled to exit a growing stockpile of ageing investments

A US private equity group has sold a large industrial business for nearly $4bn, marking one of the first big private equity windfalls from a wave of dealmaking seen in 2021, when interest rates were near zero and valuations high.

KPS Capital Partners has agreed to sell its Eviosys packaging business to manufacturer Sonoco Products nearly three years after it acquired the provider of aluminium containers for aerosols and foodstuffs like cat food, tuna and sardines, the company will announce on Monday. The deal will generate a windfall of nearly $2bn for KPS.

In 2021, KPS carved Eviosys out of Crown Holdings, a larger rival selling cans to food and beverage giants, for $2.7bn in an acquisition that came amid a record wave of $1.1tn in private equity buyouts. However, a swift increase in interest rates from early 2022 quickly cooled off buyout activity, which has fallen by more than half from those levels.

The heavy private equity investment of 2021 has caused a cash crunch among many investors like pensions and endowments because rising interest rates have punished corporate valuations and made it hard for dealmakers to exit a growing stockpile of ageing investments. The sector entered 2024 sitting on a record $3.2tn in unsold deals that are a “towering backlog” that PE firms must now exit, according to consultancy Bain & Co.

Buyout funds raised between 2019 and 2021 have collectively returned less than 20 per cent of investors’ commitments, falling “drastically behind” similar funds raised in earlier years, according to a recent report from Goldman Sachs.

KPS, however, was able to earn a swift and large windfall for Eviosys by increasing its profitability by about 50 per cent, according to a source briefed on the matter, and by identifying a larger corporate buyer that would find value in its specialised packaging operations.

Sonoco, a century-old South Carolina company which first made paper textile cones for the garments industry but now sells container for brands like Pringles chips and Bush’s Best baked beans, will pay $3.9bn for Eviosys.

Howard Coker, chief executive of Sonoco, has in recent years divested business lines focussed on recycling and industrial foam to simplify its operations.

The acquisition will generate a $1.8bn gain for KPS and its investors, or about 3.2-times their initial equity investment because they used debt to finance the deal, according to the source. KPS declined to comment on its returns.

The New York-based private equity group cofounded by Michael Psaros, which specialises in carving out non-core industrial business lines from larger conglomerates like Thyssenkrupp, Bosch, AB InBev and Tate & Lyle, has recently struck a flurry of deals.

Last month, it agreed to buy Innomotics from Siemens for $3.8bn and has agreed to two other large industrial deals this year. Managing over $21bn in total assets and known for acquiring family-owned businesses and distressed companies facing restructuring, KPS closed a $9.7bn fundraising in 2023.